• Alias: ET 743; Ecteinascidin
    • A tetrahydroisoquinoline alkaloid isolated from the marine tunicate Ecteinascidia turbinate that binds to the minor groove of DNA and inteferes with the transcription-coupled nucleotide excision repair machinery to induce lethal DNA strand breaks and blocks the cell cycle in the G2 phase.
    • FDA approved in the treatment of unresectable or metastatic soft tissue sarcoma (liposarcoma or leiomyosarcoma) in patients who have received a prior anthracycline-containing regimen.
    • Recommended dose: 1.5 mg/m2 continuous infusion over 24 hours once every 3 weeks. Premedications with dexamethasone 10 to 20 mg IV on 8 to 16 mg IV 30 minutes prior to infusion.
    Other topics in Targeted and Immunotherapy Agents